Skip to main content

Advertisement

Table 4 Comparative diagnostic performance of pre-operative standard cytology and ddPCR mutation testing

From: Analytic and clinical validity of thyroid nodule mutational profiling using droplet digital polymerase chain reaction

MEASURE Bethesda III-VI Bethesda V/VI BRAFV600E BRAFV600E + BETHESDA V/VIb BRAFV600E + H/NRASQ61K + Bethesda V/VI
Sensitivity 44.7 (30.2–59.9) 41.7 (27.6–56.8) 50 (30.7–69.4) 75.0 (55.1–89.3) 77.8 (57.7–91.4)
Specificity 70.7 (54.5–83.9) 100 (92.6–100) 100 (94.1–100) 100 (94.1–100) 98.4 (91.3–100)
PPVa 63.6 (49.7–75.6) 100 100 100 95.5 (74.8–99.3)
NPVa 52.7 (44.6–60.6) 60 (54.1–65.6) 81.3 (75.1–86.3) 89.7 (82.1–94.3) 91 (83.4–95.4)
PLR 1.53 (0.86–2.71) 48.2 (6.8–340.5)
NLR 0.78 (0.6–1.1) 0.6 (0.5–0.8) 0.5 (0.4–0.7) 0.25 (0.1–0.5) 0.2 (0.11–0.5)
  1. NLR negative likelihood ratio, NPV negative predictive value, PLR positive likelihood ratio, PPV positive predictive value
  2. aBecause the sample sizes in disease positive and disease negative groups may not reflect the true population prevalence of the disease, PPV and NPV may be inaccurate [9]. 95% confidence interval is shown in brackets where appropriate
  3. bCombined BRAF and Bethesda V/VI classifies test as positive if BRAFV600E and/or Bethesda V/VI is present